{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T03:12:04Z","timestamp":1790651524555,"version":"4.1.0"},"reference-count":39,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,6,24]],"date-time":"2026-06-24T00:00:00Z","timestamp":1782259200000},"content-version":"vor","delay-in-days":23,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["aacejournalendocrinepractice.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Endocrine Practice"],"published-print":{"date-parts":[[2026,6]]},"DOI":"10.1016\/j.eprac.2026.06.006","type":"journal-article","created":{"date-parts":[[2026,6,26]],"date-time":"2026-06-26T23:40:32Z","timestamp":1782517232000},"update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"title":["Effectiveness of GLP-1 Receptor Agonists and SGLT-2 Inhibitors Combination Therapy in Type 2 Diabetes: A Real-World Experience"],"prefix":"10.1016","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1536-5697","authenticated-orcid":false,"given":"Agostino","family":"Milluzzo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0006-0247-1860","authenticated-orcid":false,"given":"Giuseppe","family":"Quaranta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0007-2746-8104","authenticated-orcid":false,"given":"Francesco","family":"Di Giacomo Barbagallo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9021-6101","authenticated-orcid":false,"given":"Maurizio","family":"Di Marco","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nunzia","family":"Carrubba","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5210-8601","authenticated-orcid":false,"given":"Vittorio","family":"Oteri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3258-7200","authenticated-orcid":false,"given":"Laura","family":"Sciacca","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7941-5828","authenticated-orcid":false,"given":"Lucia","family":"Frittitta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.eprac.2026.06.006_bib1","doi-asserted-by":"crossref","DOI":"10.1002\/hsr2.2004","article-title":"Diabetes mellitus, the fastest growing global public health concern: early detection should be focused","volume":"7","author":"Hossain","year":"2024","journal-title":"Health Sci Rep"},{"key":"10.1016\/j.eprac.2026.06.006_bib2","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1186\/s12933-023-02065-2","article-title":"Cardiovascular risk and renal injury profile in subjects with type 2 diabetes and non-albuminuric diabetic kidney disease","volume":"22","author":"Di Marco","year":"2023","journal-title":"Cardiovasc Diabetol"},{"key":"10.1016\/j.eprac.2026.06.006_bib3","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1016\/j.numecd.2023.10.031","article-title":"Excessive generalized and visceral adiposity is associated with a higher prevalence of diabetic retinopathy in Caucasian patients with type 2 diabetes","volume":"34","author":"Tumminia","year":"2024","journal-title":"Nutr Metab Cardiovasc Dis"},{"key":"10.1016\/j.eprac.2026.06.006_bib4","doi-asserted-by":"crossref","DOI":"10.37349\/emed.2020.00013","article-title":"Type 2 diabetes and cancer: problems and suggestions for best patient management","volume":"1","author":"Milluzzo","year":"2020","journal-title":"Explor Med"},{"key":"10.1016\/j.eprac.2026.06.006_bib5","article-title":"Body mass index is related to short term retinal worsening in type 2 diabetes patients treated with anticancer drugs","author":"Milluzzo","year":"2022","journal-title":"Minerva Endocrinol"},{"key":"10.1016\/j.eprac.2026.06.006_bib6","doi-asserted-by":"crossref","DOI":"10.1080\/1120009X.2019.1572297","article-title":"Short-term adverse effects of anticancer drugs in patients with type 2 diabetes","volume":"31","author":"Milluzzo","year":"2019","journal-title":"J Chemother"},{"key":"10.1016\/j.eprac.2026.06.006_bib7","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1016\/S2213-8587(20)30343-0","article-title":"Guideline recommendations and the positioning of newer drugs in type 2 diabetes care","volume":"9","author":"Marx","year":"2021","journal-title":"Lancet Diabetes Endocrinol"},{"key":"10.1016\/j.eprac.2026.06.006_bib8","doi-asserted-by":"crossref","first-page":"173","DOI":"10.37349\/emed.2022.00083","article-title":"Semaglutide: a game changer for metabolic diseases?","author":"Milluzzo","year":"2022","journal-title":"Explor Med"},{"key":"10.1016\/j.eprac.2026.06.006_bib9","doi-asserted-by":"crossref","first-page":"5182","DOI":"10.1111\/dom.16569","article-title":"Long-term preservation of kidney function with SGLT -2 inhibitors versus comparator drugs in people with type 2 diabetes and chronic kidney disease","volume":"27","author":"Fadini","year":"2025","journal-title":"Diabetes Obes Metab"},{"key":"10.1016\/j.eprac.2026.06.006_bib10","article-title":"Long-term benefits of dapagliflozin on renal outcomes of type 2 diabetes under routine care: a comparative effectiveness study on propensity score matched cohorts at low renal risk","volume":"38","author":"Fadini","year":"2024","journal-title":"Lancet Reg Health Eur"},{"key":"10.1016\/j.eprac.2026.06.006_bib11","doi-asserted-by":"crossref","DOI":"10.1016\/j.diabres.2025.112452","article-title":"Effects of combination therapy with SGLT2 inhibitors and GLP-1 receptor agonists on CRT response and clinical outcomes in in type 2 diabetes mellitus patients receiving chronic anti-diabetic medications: a multicenter observational study","volume":"228","author":"Sardu","year":"2025","journal-title":"Diabetes Res Clin Pract"},{"key":"10.1016\/j.eprac.2026.06.006_bib12","doi-asserted-by":"crossref","DOI":"10.1016\/j.metabol.2022.155243","article-title":"SGLT2-inhibitors reduce the cardiac autonomic neuropathy dysfunction and vaso-vagal syncope recurrence in patients with type 2 diabetes mellitus: the SCAN study","volume":"137","author":"Sardu","year":"2022","journal-title":"Metabolism"},{"key":"10.1016\/j.eprac.2026.06.006_bib13","doi-asserted-by":"crossref","first-page":"9285","DOI":"10.3390\/ijms26199285","article-title":"Effects of combined therapy with SGLT2i and GLP-1RAs on atrial fibrillation recurrence after catheter ablation in diabetic cohorts: one-year outcomes from continuous monitoring","volume":"26","author":"Sardu","year":"2025","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.eprac.2026.06.006_bib14","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1186\/s12933-023-02118-6","article-title":"GLP-1 receptor agonists-SGLT-2 inhibitors combination therapy and cardiovascular events after acute myocardial infarction: an observational study in patients with type 2 diabetes","volume":"23","author":"Marfella","year":"2024","journal-title":"Cardiovasc Diabetol"},{"key":"10.1016\/j.eprac.2026.06.006_bib15","doi-asserted-by":"crossref","DOI":"10.1016\/j.diabres.2023.110766","article-title":"Impact of SGLT2-inhibitors on contrast-induced acute kidney injury in diabetic patients with acute myocardial infarction with and without chronic kidney disease: insight from SGLT2-I AMI PROTECT registry","volume":"202","author":"Paolisso","year":"2023","journal-title":"Diabetes Res Clin Pract"},{"key":"10.1016\/j.eprac.2026.06.006_bib16","doi-asserted-by":"crossref","DOI":"10.1016\/j.metabol.2024.155931","article-title":"Dcrm 2.0: multispecialty practice recommendations for the management of diabetes, cardiorenal, and metabolic diseases","volume":"159","author":"Handelsman","year":"2024","journal-title":"Metabolism"},{"key":"10.1016\/j.eprac.2026.06.006_bib17","doi-asserted-by":"crossref","first-page":"6","DOI":"10.20517\/mtod.2023.09","article-title":"Cardiovascular outcome trials of GLP-1RAs and SGLT-2 inhibitors: a concise review from the clinicians\u2019 perspective","volume":"3","author":"Min","year":"2023","journal-title":"Metab Target Organ Damage"},{"key":"10.1016\/j.eprac.2026.06.006_bib18","doi-asserted-by":"crossref","first-page":"2024","DOI":"10.1056\/NEJMra2115011","article-title":"Gliflozins in the management of cardiovascular disease","volume":"386","author":"Braunwald","year":"2022","journal-title":"New Engl J Med"},{"key":"10.1016\/j.eprac.2026.06.006_bib19","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1093\/fampra\/cmab021","article-title":"Factors associated with A1C reduction with GLP-1 agonist or SGLT-2 inhibitor use","volume":"38","author":"Davis","year":"2021","journal-title":"Fam Pract"},{"key":"10.1016\/j.eprac.2026.06.006_bib20","doi-asserted-by":"crossref","first-page":"e1","DOI":"10.1016\/j.clinthera.2019.12.012","article-title":"GLP1 receptor agonist and SGLT2 inhibitor combination: an effective approach in real-world clinical practice","volume":"42","author":"D\u00edaz-Trastoy","year":"2020","journal-title":"Clin Ther"},{"key":"10.1016\/j.eprac.2026.06.006_bib21","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1007\/s12020-016-1125-0","article-title":"Combination therapy with GLP-1 analogues and SGLT-2 inhibitors in the management of diabesity: the real world experience","volume":"55","author":"Deol","year":"2017","journal-title":"Endocrine"},{"key":"10.1016\/j.eprac.2026.06.006_bib22","doi-asserted-by":"crossref","first-page":"909","DOI":"10.1111\/dom.12897","article-title":"Glucagon-like peptide-1 receptor agonists and sodium-glucose co-transporter-2 inhibitors: sequential or simultaneous start?","volume":"19","author":"Goncalves","year":"2017","journal-title":"Diabetes Obes Metab"},{"key":"10.1016\/j.eprac.2026.06.006_bib23","doi-asserted-by":"crossref","first-page":"1315","DOI":"10.4158\/EP15877.OR","article-title":"SGLT-2 inhibitor therapy added to GLP-1 agonist therapy in the management of T2DM","volume":"21","author":"Saroka","year":"2015","journal-title":"Endocr Pract"},{"key":"10.1016\/j.eprac.2026.06.006_bib24","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1016\/j.numecd.2016.11.007","article-title":"Real-world effectiveness and safety of dapagliflozin therapy added to a GLP1 receptor agonist in patients with type 2 diabetes","volume":"27","author":"Gorgojo-Mart\u00ednez","year":"2017","journal-title":"Nutr Metab Cardiovasc Dis"},{"key":"10.1016\/j.eprac.2026.06.006_bib25","doi-asserted-by":"crossref","first-page":"68","DOI":"10.20945\/2359-3997000000440","article-title":"Dose-ranging effects of SGLT2 inhibitors in patients with type 2 diabetes: a systematic review and meta-analysis","volume":"66","author":"Pinto","year":"2022","journal-title":"Arch Endocrinol Metab"},{"key":"10.1016\/j.eprac.2026.06.006_bib26","doi-asserted-by":"crossref","DOI":"10.1136\/bmj-2023-076410","article-title":"Comparative effectiveness of GLP-1 receptor agonists on glycaemic control, body weight, and lipid profile for type 2 diabetes: systematic review and network meta-analysis","author":"Yao","year":"2024","journal-title":"BMJ"},{"key":"10.1016\/j.eprac.2026.06.006_bib27","doi-asserted-by":"crossref","first-page":"278","DOI":"10.7326\/M20-0864","article-title":"Comparative effectiveness of glucose-lowering drugs for type 2 diabetes","volume":"173","author":"Tsapas","year":"2020","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.eprac.2026.06.006_bib28","doi-asserted-by":"crossref","DOI":"10.1038\/s41574-019-0310-7","article-title":"Waist circumference as a vital sign in clinical practice: a Consensus statement from the IAS and ICCR working group on visceral obesity","volume":"16","author":"Ross","year":"2020","journal-title":"Nat Rev Endocrinol"},{"key":"10.1016\/j.eprac.2026.06.006_bib29","doi-asserted-by":"crossref","DOI":"10.3390\/jcm11030878","article-title":"Influence of body mass index, cancer type and treatment on long-term metabolic and liver outcomes in childhood cancer survivors","volume":"11","author":"Milluzzo","year":"2022","journal-title":"J Clin Med"},{"key":"10.1016\/j.eprac.2026.06.006_bib30","doi-asserted-by":"crossref","first-page":"604","DOI":"10.7326\/0003-4819-150-9-200905050-00006","article-title":"A new equation to estimate glomerular filtration rate","volume":"150","author":"Levey","year":"2009","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.eprac.2026.06.006_bib31","doi-asserted-by":"crossref","first-page":"S105","DOI":"10.2337\/dc18-S010","article-title":"10. Microvascular complications and foot care: standards of medical care in Diabetes\u20142018","volume":"41","year":"2018","journal-title":"Diabetes Care"},{"key":"10.1016\/j.eprac.2026.06.006_bib32","doi-asserted-by":"crossref","first-page":"S135","DOI":"10.2337\/dc20-S011","article-title":"11. Microvascular complications and foot care: standards of medical care in Diabetes\u22122020","volume":"43","year":"2020","journal-title":"Diabetes Care"},{"key":"10.1016\/j.eprac.2026.06.006_bib33","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1186\/s40842-018-0061-8","article-title":"Liraglutide and Dulaglutide therapy in addition to SGLT-2 inhibitor and metformin treatment in Indian type 2 diabetics: a real world retrospective observational study","volume":"4","author":"Ghosal","year":"2018","journal-title":"Clin Diabetes Endocrinol"},{"key":"10.1016\/j.eprac.2026.06.006_bib34","doi-asserted-by":"crossref","DOI":"10.1016\/j.phrs.2024.107517","article-title":"Improved glycemic and weight control with Dulaglutide addition in SGLT2 inhibitor treated obese type 2 diabetic patients at high cardiovascular risk in a real-world setting. The AWARE\u22122 study","volume":"210","author":"Berra","year":"2024","journal-title":"Pharmacol Res"},{"key":"10.1016\/j.eprac.2026.06.006_bib35","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1111\/j.1464-5491.2010.02941.x","article-title":"Relationship of baseline HbA 1c and efficacy of current glucose-lowering therapies: a meta-analysis of randomized clinical trials","volume":"27","author":"DeFronzo","year":"2010","journal-title":"Diabetic Med"},{"key":"10.1016\/j.eprac.2026.06.006_bib36","doi-asserted-by":"crossref","first-page":"1353","DOI":"10.1111\/dom.12982","article-title":"Combination therapy with GLP -1 receptor agonist and SGLT2 inhibitor","volume":"19","author":"DeFronzo","year":"2017","journal-title":"Diabetes Obes Metab"},{"key":"10.1016\/j.eprac.2026.06.006_bib37","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1172\/JCI72227","article-title":"Metabolic response to sodium-glucose cotransporter 2 inhibition in type 2 diabetic patients","volume":"124","author":"Ferrannini","year":"2014","journal-title":"J Clin Invest"},{"key":"10.1016\/j.eprac.2026.06.006_bib38","doi-asserted-by":"crossref","first-page":"6210","DOI":"10.1111\/dom.70005","article-title":"Effectiveness of GLP - 1RA according to different type 2 diabetes phenotypes: a retrospective study","volume":"27","author":"Caruso","year":"2025","journal-title":"Diabetes Obes Metab"},{"key":"10.1016\/j.eprac.2026.06.006_bib39","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1186\/1758-5996-6-110","article-title":"Prediction of response to GLP-1 receptor agonist therapy in Japanese patients with type 2 diabetes","volume":"6","author":"Imai","year":"2014","journal-title":"Diabetol Metab Syndr"}],"container-title":["Endocrine Practice"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1530891X26010402?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1530891X26010402?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,7,14]],"date-time":"2026-07-14T11:34:46Z","timestamp":1784028886000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1530891X26010402"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6]]},"references-count":39,"alternative-id":["S1530891X26010402"],"URL":"https:\/\/doi.org\/10.1016\/j.eprac.2026.06.006","relation":{},"ISSN":["1530-891X"],"issn-type":[{"value":"1530-891X","type":"print"}],"subject":[],"published":{"date-parts":[[2026,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Effectiveness of GLP-1 Receptor Agonists and SGLT-2 Inhibitors Combination Therapy in Type 2 Diabetes: A Real-World Experience","name":"articletitle","label":"Article Title"},{"value":"Endocrine Practice","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.eprac.2026.06.006","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 AACE. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}